Dianthus Therapeutics Hits Early “Go” in CAPTIVATE Phase 3 CIDP Trial, Drops 600 mg Arm [Yahoo! Finance]
Dianthus Therapeutics, Inc. (DNTH)
Company Research
Source: Yahoo! Finance
goal (20 confirmed NCAT responders) and raised the Part A responder assumption to 50%, leading it to drop the 600 mg arm and make Part B a two-arm randomized withdrawal of 300 mg every two weeks versus placebo. Reassuring safety signal: The interim analysis reported no concerning safety events, no indications of autoimmune activation (including drug-induced lupus), and no safety-related discontinuations. Pipeline and financing: Management reiterated plans for a mid-2026 gMG Phase 3 start (top-line 2H 2028), MMN and DNTH212 near-term readouts, and a cash balance of about $514 million projected to fund operations into 2028. Interested in Dianthus Therapeutics, Inc.? Here are five stocks we like better. Dianthus Therapeutics (NASDAQ:DNTH) said it has made an “early go” decision to continue its CAPTIVATE Phase 3 trial evaluating claseprubart in chronic inflammatory demyelinating polyneuropathy (CIDP), based on a planned interim responder analysis from Part A of the ongoing pivotal
Show less
Read more
Impact Snapshot
Event Time:
DNTH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DNTH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DNTH alerts
High impacting Dianthus Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
DNTH
News
- Dianthus Therapeutics (DNTH) is now covered by Wells Fargo & Company. They set an "overweight" rating and a $135.00 price target on the stock.MarketBeat
- Wedbush Keeps Outperform on Dianthus Therapeutics, Inc. (DNTH), Highlights Potential of Claseprubart in CIDP [Yahoo! Finance]Yahoo! Finance
- Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit [Yahoo! Finance]Yahoo! Finance
- Dianthus Therapeutics (DNTH) had its "outperform" rating reaffirmed by William Blair.MarketBeat
- Dianthus Therapeutics (DNTH) Is Up 30.8% After Upsized Raise And Early Phase 3 “Go” Decision [Yahoo! Finance]Yahoo! Finance
DNTH
Earnings
- 3/9/26 - Miss
DNTH
Sec Filings
- 3/24/26 - Form 144
- 3/17/26 - Form 4
- 3/13/26 - Form 4
- DNTH's page on the SEC website